Wells Fargo & Company Issues Pessimistic Forecast for Inspire Medical Systems (NYSE:INSP) Stock Price

Inspire Medical Systems (NYSE:INSP) had its price objective decreased by equities research analysts at Wells Fargo & Company from $198.00 to $195.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 4.18% from the stock’s current price.

Several other research analysts also recently commented on the stock. Bank of America raised shares of Inspire Medical Systems from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $220.00 to $255.00 in a report on Wednesday, November 20th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $260.00 price target on shares of Inspire Medical Systems in a report on Tuesday, November 5th. Piper Sandler reduced their price target on Inspire Medical Systems from $260.00 to $233.00 and set an “overweight” rating for the company in a research report on Monday. Stifel Nicolaus dropped their price objective on Inspire Medical Systems from $200.00 to $190.00 and set a “hold” rating on the stock in a report on Tuesday, January 21st. Finally, Robert W. Baird lifted their target price on Inspire Medical Systems from $240.00 to $252.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $228.82.

Inspire Medical Systems Price Performance

Shares of INSP opened at $187.17 on Tuesday. Inspire Medical Systems has a 1 year low of $123.00 and a 1 year high of $257.40. The stock’s fifty day moving average price is $189.39 and its two-hundred day moving average price is $191.39. The firm has a market cap of $5.61 billion, a PE ratio of 174.93 and a beta of 1.32.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, February 10th. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. Sell-side analysts anticipate that Inspire Medical Systems will post 1.33 earnings per share for the current fiscal year.

Institutional Trading of Inspire Medical Systems

A number of large investors have recently modified their holdings of INSP. First Horizon Advisors Inc. raised its stake in Inspire Medical Systems by 885.7% in the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock valued at $26,000 after purchasing an additional 124 shares in the last quarter. True Wealth Design LLC purchased a new stake in shares of Inspire Medical Systems during the 3rd quarter valued at $30,000. Farther Finance Advisors LLC raised its position in shares of Inspire Medical Systems by 1,158.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock valued at $32,000 after buying an additional 139 shares in the last quarter. Huntington National Bank raised its position in shares of Inspire Medical Systems by 228.3% during the 4th quarter. Huntington National Bank now owns 174 shares of the company’s stock valued at $32,000 after buying an additional 121 shares in the last quarter. Finally, Harbour Investments Inc. lifted its holdings in shares of Inspire Medical Systems by 101.0% during the 4th quarter. Harbour Investments Inc. now owns 197 shares of the company’s stock worth $37,000 after acquiring an additional 99 shares during the last quarter. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.